First-line immunotherapy fails to improve OS outside of trials for older adults with NSCLC Disclosures: The Doris Duke Charitable Foundation, Health Data Analytics Institute, NCI, Simeon J. Fortin Foundation and Wong Family Foundation supported the study. Kehl reports personal fees from Aetion, IBM Corporation and Roche outside the submitted work. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS You've successfully added to your alerts. You will receive an email when new content is published.